New article in SA, we are one out of 4 companies r

Quote:

---

I believe the world and investors should be paying attention to some of the preliminary results that are being observed in these EIND patients over the next week or so. Admittedly, I can't find any strong data about the survival rate for severely ill COVID-19 patients, however, I think it's safe to say that being put on a ventilator is not a good scenario. If CytoDyn continues to report that they are seeing "rapid and positive laboratory responses", we should expect an increase in attention from the media and the market. So far, we have heard mostly anecdotal evidence about hydroxychloroquine and chloroquine but the healthcare community is 100% sold on its safety and efficacy for COVID-19, especially in cardiac patients. In addition, I can't find any solid information on who is getting it… patients with moderate symptoms? Severely ill? I'm not saying it won't have its place in this fight, but it doesn't seem like these antimalarial drugs are going to be a universal use. On the other hand, Leronlimab has already shown efficacy in other indications and has an impressive safety profile in immunocompromised HIV and cancer patients.

Overall, CytoDyn might have one of only a few legitimate COVID-19 products that could be readily deployed if the FDA approves its emergency use. This would be a major win for a small-cap biotech that is looking to get Leronlimab approved for HIV and transition into a commercial level company.

---